NXOA Stock Overview
Nicox S.A. operates as an ophthalmology company in France and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Nicox S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.34 |
52 Week High | €0.60 |
52 Week Low | €0.26 |
Beta | 0.89 |
1 Month Change | -0.44% |
3 Month Change | -7.93% |
1 Year Change | -42.34% |
3 Year Change | -91.60% |
5 Year Change | -93.05% |
Change since IPO | -99.17% |
Recent News & Updates
Recent updates
Shareholder Returns
NXOA | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.1% | 1.8% | -0.3% |
1Y | -42.3% | -19.9% | 2.8% |
Return vs Industry: NXOA underperformed the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: NXOA underperformed the German Market which returned 2.8% over the past year.
Price Volatility
NXOA volatility | |
---|---|
NXOA Average Weekly Movement | 8.0% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NXOA's share price has been volatile over the past 3 months.
Volatility Over Time: NXOA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 28 | Gavin Spencer | www.nicox.com |
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Nicox S.A. Fundamentals Summary
NXOA fundamental statistics | |
---|---|
Market cap | €18.80m |
Earnings (TTM) | -€17.36m |
Revenue (TTM) | €3.57m |
5.3x
P/S Ratio-1.1x
P/E RatioIs NXOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NXOA income statement (TTM) | |
---|---|
Revenue | €3.57m |
Cost of Revenue | €16.90m |
Gross Profit | -€13.33m |
Other Expenses | €4.03m |
Earnings | -€17.36m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.35 |
Gross Margin | -372.97% |
Net Profit Margin | -485.70% |
Debt/Equity Ratio | 44.8% |
How did NXOA perform over the long term?
See historical performance and comparison